Emphasis on Technology (Monoclonal Antibodies, Cell And Gene Therapies, Cytokines, Others); Application (Lung Cancer, Breast Cancer, Melanoma Cancer, Prostate Cancer, Others); End-Users (Hospitals, Radiation Therapy Centers, Cancer Research Institutes); and Region/Country
The Intratumoral cancer therapies market was valued at USD 151.5 million in 2022 & is expected to grow at a CAGR of 9.9% from 2023-2030. Intratumoral cancer therapies are a type of cancer treatment that involves delivering therapeutic agents directly into the tumour site. Unlike systemic treatments, which circulate throughout the entire body, intratumoral therapies target cancer cells within the tumour while minimizing exposure to healthy tissues. Growing advancements in immunotherapy, including immune checkpoint inhibitors, CAR-T cell therapies, and oncolytic viruses, are driving interest in intratumoral applications. These therapies stimulate the body’s immune response to target and destroy cancer cells directly within the tumour site. For instance, in February 2021, the FDA approved Merck’s Keytruda (pembrolizumab) for the treatment of high-risk, non-muscle invasive bladder cancer unresponsive to BCG therapy. This approval highlights the potential of immunotherapies in intratumoral applications. Furthermore, the trend toward personalized medicine is driving the development of intratumoral therapies tailored to individual patients’ genetic profiles and tumour characteristics. This approach improves treatment effectiveness and reduces side effects.
Some of the major players operating in the market are AstraZeneca, Amgen Inc., Eli Lilly and Company, AbbVie Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Merck & Co., Inc, Bayer AG, Pfizer Inc., Bristol-Myers Squibb Co. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.
Insights Presented in the Report
“Amongst Technology, the monoclonal antibodies segment held a significant share of the market in 2022.”
Based on the technology, the market has been categorized into monoclonal antibodies, cell and gene therapies, cytokines, and others. Among them, the monoclonal antibodies segment is expected to grow at a higher CAGR in the market due to their potential to target specific cancer cells, trigger immune responses, and minimize off-target effects. Monoclonal antibodies have been widely used in systemic cancer treatments, and their application in intratumoral therapies is gaining traction due to their precision and effectiveness. For instance, GSK’s antibody-drug conjugate, Blenrep (belantamab mafodotin-blmf), was granted FDA approval for the treatment of relapsed or refractory multiple myeloma.
“Amongst Application, the lung cancer segment held a significant share of the market in 2022.”
Based on the application, the market has been categorized into lung cancer, breast, melanoma, prostate cancer, and others. Among them, the lung cancer segment is expected to grow at a higher CAGR in the market due to the high incidence of lung cancer and the increasing adoption of innovative therapies to address this challenging disease. Moreover, standard treatments for lung cancer, such as surgery, chemotherapy, and radiation, can have limitations and significant side effects. Intratumoral therapies aim to address these challenges by targeting the tumor cells while minimizing damage to healthy tissues. For instance, in 2021, Varian Medical Systems, are developing innovative techniques for localized treatment of NSCLC, including intratumoral therapies named Elekta. These techniques aim to target tumours within the lung while minimizing damage to healthy lung tissue.
“Amongst end-user, the hospitals segment held the higher CAGR in the market in 2022.”
Based on the end-user, the market has been categorized into hospitals, radiation therapy center, and cancer research institutes. Among them, the hospital category is to witness higher adoption of intratumoral cancer therapies during the forecast period. The rising incidence of cancer and the growing awareness of cancer among the general population has led to an increased number of patients seeking medical attention and technology at hospitals. In addition, hospitals offer a multidisciplinary approach to bringing together various specialists such as endocrinologists, surgical oncologists, medical oncologists, radiologists, and pathologists to provide comprehensive and personalized care to cancer patients. Moreover, Hospitals often have surgical teams experienced in performing complex thyroid surgeries, including total thyroidectomy and lymph node dissection, which are essential in the management of cancer.
“North America dominated the intratumoral cancer therapies market in 2022.”
The North America intratumoral cancer therapies market is expected to continue to grow in the coming years, driven by the increasing prevalence of cancer and growing awareness of intratumoral cancer therapies among healthcare professionals and the general population, development of advanced imaging techniques and the rise in treatment option. For instance, in 2020, according to American Cancer Society, Cancer is the second most common cause of death in the US, exceeded only by heart disease. around 609,360 deaths from cancer are expected in the US in 2022, which is about 1,670 deaths per day.
Intratumoral cancer therapies Market Report Coverage
Reasons to buy this report:
Customization Options:
The global Intratumoral cancer therapies market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
1. Market Introduction
2. Research Methodology Or Assumption
3. Market Synopsis
4. Executive Summary
5. Impact Of Covid-19 On The Intratumoral Cancer Therapies Market
6. Global Intratumoral Cancer Therapies Market Revenue, 2020-2030f
7. Market Insights By Technology
8. Market Insights By Application
9. Market Insights By End-users
10. Market Insights By Region
11. Intratumoral Cancer Therapies Market Dynamics
12. Intratumoral Cancer Therapies Market Opportunities
13. Intratumoral Cancer Therapies Market Trends & Insights
14. Demand And Supply-side Analysis
15. Value Chain Analysis
16. Pricing Analysis
17. Competitive Scenario
18. Company Profiled
19. Disclaimer
Research Methodology for the Intratumoral Cancer Therapies Market Analysis (2023-2030)
Analyzing the historical market, estimating the current market, and forecasting the future market of the global Intratumoral cancer therapies market were the three major steps undertaken to create and analyze the adoption of Intratumoral cancer therapies in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global Intratumoral cancer therapies market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:
Analysis of Historical Market Size
Step 1: In-Depth Study of Secondary Sources:
Detail secondary study was conducted to obtain the historical market size of the Intratumoral cancer therapies market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the Intratumoral cancer therapies market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as technology, application and end-users. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the Intratumoral cancer therapies market. Further, we conducted factor analysis using dependent and independent variables such as technology, application and end-users of the Intratumoral cancer therapies market. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the Intratumoral cancer therapies market sector across the globe.
Current Market Size Estimate & Forecast
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global Intratumoral cancer therapies market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2030 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
Market Size and Share Validation
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
Split of Primary Participants in Different Regions
Market Engineering
The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global Intratumoral cancer therapies market. data was split into several segments & sub-segments post studying various parameters and trends in the areas of the technology, application and end-users in the global Intratumoral cancer therapies market.
The main objective of the Global Intratumoral cancer therapies Market Study
The current & future market trends of the global Intratumoral cancer therapies market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
